Neurofibromatosis Type 1

• NF1 gene mutation and loss of function: Mutations in the NF1 gene (chromosome 17q11.2) result in loss or dysfunction of neurofibromin, a cytoplasmic protein that acts as a GTPase-activating protein (GAP) for RAS. Loss of neurofibromin function leads to constitutive RAS-MAPK pathway activation, promoting uncontrolled cell proliferation. Approximately 50% of cases result from de novo mutations, while 50% are inherited in autosomal dominant fashion.

• Cellular consequences of RAS hyperactivation: Dysregulation of the RAS/RAF/MEK/ERK signaling cascade drives proliferation of neural crest-derived cells, particularly Schwann cells and melanocytes. This results in neurofibromas (benign proliferations of Schwann cells, fibroblasts, and other cell types), cutaneous manifestations, and predisposition to malignant transformation. Impaired neurofibromin function also disrupts cell cycle checkpoints and apoptotic pathways.

• Two-hit hypothesis and tumor development: While all somatic cells carry the germline NF1 mutation, tumorigenesis typically requires a second somatic "hit" affecting the remaining wild-type NF1 allele in localized cell populations. This explains why neurofibromas develop focally rather than diffusely, and why risk of malignant transformation increases with time and tumor burden. MPNST development involves additional mutations in TP53, PTEN, or other tumor suppressors.

• Germline NF1 mutations: Approximately 50% of NF1 cases arise from de novo mutations with no family history. The remaining 50% result from autosomal dominant inheritance from an affected parent. Mutations include deletions, point mutations, insertions, and splice site alterations. Certain mutation types (whole-gene deletions, truncating mutations) correlate with more severe phenotypes.

• Age-related accumulation of somatic mutations: While individuals are born with one mutated NF1 allele in all cells, somatic "second hits" accumulate over time in specific cell populations, explaining the progressive nature of neurofibromas and increasing malignancy risk with advancing age.

Early manifestations (childhood)

• Café-au-lait macules: Appear in infancy/early childhood; hyperpigmented macules present in >99% of NF1 patients. Diagnostic criteria require ≥6 lesions each >5 mm diameter (prepubertal) or >15 mm (postpubertal). Increase in number and size during childhood, often stabilizing in adulthood.
• Optic nerve pathway gliomas (ONPGs): Affect 15-20% of NF1 patients clinically; found in 40-70% on imaging. Usually asymptomatic and non-progressive; may cause visual impairment, proptosis, or precocious puberty if hypothalamic involvement occurs.
• Freckling: Intertriginous freckling in axillae, groin, and other skin flexures is pathognomonic; appears after café-au-lait spots.
• Lisch nodules: Benign iris hamartomas appearing as brown nodules on slit-lamp examination; present in ~75% of affected adults; increase with age but do not affect vision.
• Short stature and macrocephaly: Present in approximately 30-40% and 50% of NF1 patients, respectively.

Progressive manifestations (adolescence/adulthood)

• Cutaneous neurofibromas: Begin appearing in puberty/early adulthood; initially few but can proliferate to hundreds over time. Patients may develop severe disfigurement and functional impairment with large plexiform neurofibromas.
• Plexiform neurofibromas: Deep infiltrative tumors arising from nerve plexuses; present in ~25% of NF1 patients, often clinically silent but detectable on imaging. Risk of malignant transformation to MPNST is 8-13% lifetime, increasing with age and tumor burden.
• Skeletal manifestations: Dysplasia (long bone bowing, vertebral scalloping), scoliosis (10-25% of NF1 patients), long bone pseudarthrosis, kyphosis.
• Neurological complications: Learning disabilities (40-60%), attention-deficit/hyperactivity disorder (ADHD), autism spectrum features, hypertension (cerebral vasculopathy or pheochromocytoma-related).
• Pheochromocytoma: Occurs in 1-5% of NF1 patients; may present with episodic hypertension, palpitations, sweating, or headache.

Physical examination findings

• Hyperpigmented macules with smooth borders (café-au-lait spots)
• Fine papulonodular skin lesions (cutaneous neurofibromas)
• Visible/palpable subcutaneous nodules along nerve distributions
• Iris hamartomas on slit-lamp examination (Lisch nodules)
• Signs of neurofibromatosis-related complications: skeletal deformities, neurological deficits, evidence of hypertension

1. 1.Six or more café-au-lait macules (>5 mm diameter in prepubertal; >15 mm in postpubertal individuals)
2. 2.Two or more neurofibromas (any type) or one plexiform neurofibroma
3. 3.Freckling in axillae or groin
4. 4.Optic nerve pathway glioma (confirmed on imaging)
5. 5.Two or more Lisch nodules (iris hamartomas on slit-lamp examination)
6. 6.Characteristic bony lesion (sphenoid wing dysplasia, long bone dysplasia with pseudarthrosis)
7. 7.First-degree relative with NF1 meeting above criteria
8. 8.Pathogenic NF1 gene mutation on genetic testing

Genetic testing

• Sequence analysis and deletion/duplication testing: Identifies NF1 mutations in ~95% of clinically diagnosed NF1 patients. Full-gene sequencing is preferred for diagnostic confirmation and family planning.
• Chromosomal microarray: Detects large deletions (whole NF1 gene or contiguous regions) associated with severe phenotypes.

Imaging studies

• MRI of brain/spine: Identifies optic pathway gliomas, T2 hyperintense foci (unidentified bright objects; UBOs), and structural abnormalities (scoliosis, spinal dysplasia).
• MRI or CT of affected regions: Assesses plexiform neurofibromas and their relationship to vital structures; useful for surgical planning.
• Whole-body MRI or PET-CT: Reserved for surveillance of malignancy in high-risk patients or when MPNST is suspected.

Laboratory and clinical assessment

• 24-hour urine metanephrines and plasma free metanephrines: Screening for pheochromocytoma (10-year intervals recommended after age 40).
• Ophthalmologic examination with slit lamp: Identifies Lisch nodules and assesses visual function.
• Baseline neuropsychological testing: Establishes cognitive/learning status in children.
• Audiology assessment: Evaluates for sensorineural hearing loss (occurring in ~20% of NF1 patients).

• Annual dermatologic examination: Monitor for malignant transformation of cutaneous lesions; baseline photography helpful for tracking.
• Annual ophthalmologic examination: Slit-lamp assessment for Lisch nodules; visual acuity testing; fundoscopy. Formal visual field testing and neuroimaging only if symptoms develop.
• Blood pressure monitoring: Annual screening; investigate hypertension with plasma metanephrines/24-hour urine metanephrines and imaging (CT or MRI abdomen) if elevated.
• Baseline MRI of brain/spine: Assess for OPGs, UBOs, and structural abnormalities; repeat only if symptoms develop (asymptomatic OPGs do not require routine follow-up imaging).
• Periodic metanephrine screening: Every 5-10 years beginning in adolescence/young adulthood.

Management of asymptomatic lesions

• Asymptomatic optic pathway gliomas: Observation only; do not treat with chemotherapy or radiation absent symptoms (vision loss, proptosis, hypothalamic dysfunction).
• Asymptomatic cutaneous neurofibromas: Reassurance and cosmetic counseling; surgical excision for disfiguring lesions if patient desires.
• Asymptomatic plexiform neurofibromas: Surveillance imaging (MRI every 2-3 years if large or positioned near vital structures); surgical intervention only if causing functional impairment or risk of malignancy.

Management of symptomatic lesions and complications

• Chemotherapy (carboplatin ± vincristine): First-line for progressive gliomas causing vision compromise; chemotherapy preferred over radiation to avoid secondary malignancy risk in NF1 population.
• Radiation therapy: Reserved for chemotherapy-resistant progressive disease; increases risk of secondary malignancy.

• Surgical resection: Definitive treatment after medical optimization.
• Preoperative preparation: Alpha-adrenergic blockade (phenoxybenzamine or doxazosin) followed by beta-blockade (metoprolol or atenolol); reduces perioperative cardiovascular complications.

• Surgical excision: For cosmetically disfiguring lesions or those causing functional impairment (nerve compression, pain).
• Dermatologic lasers: Emerging modality for small cutaneous lesions.
• Topical applications: Limited evidence; investigational compounds (e.g., imiquimod, curcumin) lack proven efficacy.

• Observation: Most remain stable; intervention only if causing pain, functional impairment, or rapid growth.
• Surgical resection: Indicated for lesions causing compression of vital structures, pain, or disfigurement; must balance functional benefit against risk of nerve injury.
• Systemic therapy for progressive disease: MEK inhibitors (selumetinib) approved by FDA (2020) for inoperable plexiform neurofibromas in pediatric and young adult patients; inhibits downstream RAS/MAPK signaling. Produces volumetric reduction in ~70% of treated tumors.

• Surgical resection: Primary treatment; wide margins necessary.
• Adjuvant chemotherapy: Doxorubicin ± ifosfamide; improves outcomes in advanced/metastatic MPNST, though long-term survival remains poor.
• Radiation therapy: Adjuvant radiotherapy for high-grade or incompletely resected tumors.
• Molecular targeted therapy: Under investigation; activity of MEK inhibitors and other agents limited.

• Scoliosis: Orthotic management for mild cases; surgical fusion for severe progressive disease (>40-50 degrees).
• Pseudarthrosis: Requires aggressive surgical intervention with fixation and vascularized bone grafting.
• Dysplasia/bowing deformities: Surgical correction for functional impairment or limb-length discrepancy.

• Formal neuropsychological evaluation: Establishes baseline and identifies specific deficits.
• Educational support: Individualized education plan (IEP) in school settings; tutoring for specific learning disabilities.
• ADHD management: Stimulant medications (methylphenidate, amphetamine) or atomoxetine as indicated.

Non-pharmacological measures

• Genetic counseling: Preconception counseling in reproductive-age patients; discussion of 50% transmission risk.
• Psychosocial support: Addressing disfigurement, anxiety, depression common in NF1 populations; support groups valuable.
• Occupational/physical therapy: Addresses functional limitations from skeletal deformities or neurofibromas.

Malignant transformation

• Malignant peripheral nerve sheath tumors (MPNSTs): Most feared complication; lifetime risk 8-13% in NF1 patients (vs. <0.001% general population). May arise de novo or from pre-existing plexiform neurofibroma. Present with rapid growth, pain, neurological deficits. Diagnosis confirmed by imaging (MRI/PET-CT) and often tissue biopsy. Treatment involves surgical resection and chemotherapy, but prognosis remains poor (5-year survival ~50% even with aggressive therapy). Screen for MPNST with imaging if rapid growth or new pain develops.
• Other malignancies: Increased risk of breast cancer (40-50% by age 70 in women; earlier onset), pheochromocytoma, optic pathway gliomas (usually indolent but potential for progression), gastrointestinal stromal tumors (GISTs), and others.

Cardiovascular and cerebrovascular complications

• Hypertension: Results from pheochromocytoma (1-5% of patients) or NF1-related cerebral vasculopathy (dysplasia of cerebral vessels with risk of stroke). Manage with antihypertensive therapy; screen for pheochromocytoma if hypertension detected.
• Stroke: Risk increased from vasculopathy; acute management standard.
• Cardiac involvement: Rare but includes cardiomyopathy, coronary artery stenosis from neurofibromatosis of coronary vessels.

Neurological complications

• Learning disabilities and ADHD: Affect 40-60% and ~50% of NF1 children, respectively. Manage with educational support and pharmacotherapy as outlined above.
• Seizures: Occur in 5-10% of NF1 patients; may result from brain gliomas, cortical dysplasia, or other mechanisms. Treat with standard antiepileptic drugs.
• Headaches and migraine: Increased prevalence; treat symptomatically.
• Cognitive impairment: Variable severity; early intervention and educational support improve outcomes.

Auditory and visual complications

• Sensorineural hearing loss: Affects ~20% of NF1 patients; may result from auditory nerve involvement or other mechanisms. Screen with audiometry; hearing aids recommended.
• Vision impairment from optic pathway gliomas: Ranges from asymptomatic to severe visual loss; chemotherapy indicated if progressive.

Orthopedic complications

• Scoliosis: Develops in 10-25% of NF1 patients, often early-onset and severe. Dysplastic curves progress more rapidly than idiopathic scoliosis. Management outlined above.
• Long bone pseudarthrosis: Rare but disabling complication requiring aggressive surgical intervention.
• Limb-length discrepancy: Results from bone dysplasia; may require surgical correction.

Cutaneous and soft tissue complications

• Severe cutaneous neurofibromatosis: Development of hundreds of neurofibromas causing disfigurement, pain, and functional impairment. Surgical debulking helpful but recurrence common.
• Skin infections: Increased risk in areas with multiple neurofibromas.

Reproductive and pregnancy-related complications

• **Cesarean

Buzzwords that identify the disease

• Chromosome 17, neurofibromin, RAS-GAP: NF1 is von Recklinghausen disease — "NF17" versus NF2 on chromosome 22 (merlin, bilateral vestibular schwannomas, juvenile cataracts). Autosomal dominant with near-complete penetrance but highly variable expressivity, so an affected parent can be mildly affected while the child is severely so.
• Crowe sign: axillary/inguinal freckling — the most specific cutaneous clue; café-au-lait macules in NF1 have smooth "coast of California" borders.
• Lisch nodules: pigmented iris hamartomas seen only on slit lamp; visually harmless but diagnostically decisive.
• Optic pathway glioma: histologically a pilocytic astrocytoma — Rosenthal fibers, GFAP-positive, WHO grade 1. The T2-hyperintense "unidentified bright objects" on MRI are not tumors and need no treatment.

Single best next step scenarios

• Plexiform neurofibroma with new pain, rapid growth, or a new neurologic deficit: think MPNST — the next step is MRI of the lesion (PET-CT/biopsy to follow), not reassurance.
• Hypertension in an NF1 patient: screen for pheochromocytoma with plasma free metanephrines (Endocrine Society guideline) and consider renal artery stenosis from NF1 vasculopathy, a classic cause of secondary hypertension in NF1 children.
• Inoperable, symptomatic plexiform neurofibroma in a child: MEK inhibitor (selumetinib), FDA-approved for this indication, targeting the hyperactive RAS-MAPK cascade.

Distractors to avoid

• McCune-Albright syndrome: irregular "coast of Maine" café-au-lait macules, polyostotic fibrous dysplasia, precocious puberty — not NF1.
• Legius syndrome (SPRED1): café-au-lait macules plus freckling but no neurofibromas, Lisch nodules, or gliomas.
• Diagnosis is clinical by NIH criteria; genetic testing is confirmatory, not required when criteria are met.
• Tuberous sclerosis gives ash-leaf hypopigmented macules, not hyperpigmented ones.